Validation of serum non‐invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia

Documenti analoghi

• Regression of liver fibrosis after HBsAg loss: A prospective matched case–control evaluation using transient elastography and serum enhanced liver fibrosis test
  di: Lung‐Yi Mak, et al.
  Pubblicazione: (2024)
• Metabolic‐associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy
  di: NM Batt, et al.
  Pubblicazione: (2024)
• Vitamin E improves serum markers and histology in adults with metabolic dysfunction‐associated steatotic liver disease: Systematic review and meta‐analysis
  di: Nicholas Ming‐Zher Chee, et al.
  Pubblicazione: (2024)
• Relevance of combined influence of nutritional and inflammatory status on non‐alcoholic fatty liver disease and advanced fibrosis: A mediation analysis of lipid biomarkers
  di: Lei Pan, et al.
  Pubblicazione: (2024)
• TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation
  di: Jingjie Wang, et al.
  Pubblicazione: (2024)